Oncology Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
Oncology ASCO 2026: Powerful evidence for the microbiome in oncology,... Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
Oncology Bridging the cancer drug development gap: AI-driven precisio... Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.
Oncology ASCO 2026: Are radiopharmaceuticals being systematically und... The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.
Oncology ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B... Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
Oncology After Pluvicto: Alpha radiopharma and prostate cancer Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.
Oncology Dr Michael Bauer on Quantro’s mission to drug the “undruggab... Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
